On August 5, 2020, clonoSEQ® (Adaptive Biotechnologies®), a next-generation sequencing assay that detects and monitors measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL), received U.S. Food and Drug Administration (FDA) clearance for MRD assessment in blood and bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is covered by Medicare for these indications.
Read the Press Release. For prescribing information and test limitations view the clonoSEQ Technical Summary.
On August 5, 2020, clonoSEQ® (Adaptive Biotechnologies®), a next-generation sequencing assay that detects and monitors measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL), received U.S. Food and Drug Administration (FDA) clearance for MRD assessment in blood and bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is covered by Medicare for these indications.
Read the Press Release. For prescribing information and test limitations view the clonoSEQ Technical Summary.
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
